Literature DB >> 31889890

Type I Error Probability Spending for Post-Market Drug and Vaccine Safety Surveillance With Poisson Data.

Ivair R Silva1.   

Abstract

Statistical sequential hypothesis testing is meant to analyze cumulative data accruing in time. The methods can be divided in two types, group and continuous sequential approaches, and a question that arises is if one approach suppresses the other in some sense. For Poisson stochastic processes, we prove that continuous sequential analysis is uniformly better than group sequential under a comprehensive class of statistical performance measures. Hence, optimal solutions are in the class of continuous designs. This paper also offers a pioneer study that compares classical Type I error spending functions in terms of expected number of events to signal. This was done for a number of tuning parameters scenarios. The results indicate that a log-exp shape for the Type I error spending function is the best choice in most of the evaluated scenarios.

Entities:  

Keywords:  Expected number of events to signal; Log-exp alpha spending; Sequential probability ratio test

Year:  2017        PMID: 31889890      PMCID: PMC6936745          DOI: 10.1007/s11009-017-9586-z

Source DB:  PubMed          Journal:  Methodol Comput Appl Probab        ISSN: 1387-5841            Impact factor:   1.147


  8 in total

1.  Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data.

Authors:  Jennifer C Nelson; Andrea J Cook; Onchee Yu; Clara Dominguez; Shanshan Zhao; Sharon K Greene; Bruce H Fireman; Steven J Jacobsen; Eric S Weintraub; Lisa A Jackson
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01       Impact factor: 2.890

2.  Active surveillance of vaccine safety: a system to detect early signs of adverse events.

Authors:  Robert L Davis; Margarette Kolczak; Edwin Lewis; James Nordin; Michael Goodman; David K Shay; Richard Platt; Steven Black; Henry Shinefield; Robert T Chen
Journal:  Epidemiology       Date:  2005-05       Impact factor: 4.822

3.  Real-time vaccine safety surveillance for the early detection of adverse events.

Authors:  Tracy A Lieu; Martin Kulldorff; Robert L Davis; Edwin M Lewis; Eric Weintraub; Katherine Yih; Ruihua Yin; Jeffrey S Brown; Richard Platt
Journal:  Med Care       Date:  2007-10       Impact factor: 2.983

4.  Group sequential designs using a family of type I error probability spending functions.

Authors:  I K Hwang; W J Shih; J S De Cani
Journal:  Stat Med       Date:  1990-12       Impact factor: 2.373

5.  A multiple testing procedure for clinical trials.

Authors:  P C O'Brien; T R Fleming
Journal:  Biometrics       Date:  1979-09       Impact factor: 2.571

6.  Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project.

Authors:  W Katherine Yih; Martin Kulldorff; Bruce H Fireman; Irene M Shui; Edwin M Lewis; Nicola P Klein; James Baggs; Eric S Weintraub; Edward A Belongia; Allison Naleway; Julianne Gee; Richard Platt; Tracy A Lieu
Journal:  Pediatrics       Date:  2011-04-18       Impact factor: 7.124

7.  Continuous versus group sequential analysis for post-market drug and vaccine safety surveillance.

Authors:  I R Silva; M Kulldorff
Journal:  Biometrics       Date:  2015-05-22       Impact factor: 2.571

Review 8.  Near real-time vaccine safety surveillance using electronic health records-a systematic review of the application of statistical methods.

Authors:  Andreia Leite; Nick J Andrews; Sara L Thomas
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-01-28       Impact factor: 2.890

  8 in total
  1 in total

1.  Alpha spending for historical versus surveillance Poisson data with CMaxSPRT.

Authors:  Ivair R Silva; Wilson M Lopes; Philipe Dias; W Katherine Yih
Journal:  Stat Med       Date:  2019-01-28       Impact factor: 2.373

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.